

Adamas Pharmaceuticals Inc  
 Form 4  
 October 07, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Went Gregory T

2. Issuer Name and Ticker or Trading Symbol  
 Adamas Pharmaceuticals Inc  
 [ADMS]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 10/05/2016

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chief Executive Officer

C/O ADAMAS  
 PHARMACEUTICALS, INC., 1900  
 POWELL ST., SUITE 750

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

EMERYVILLE, CA 94608

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4)     |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| Common Stock                    | 10/05/2016                           |  | J <sup>(1)</sup>               | 117,450 D   | \$ 0 146,208  | D  |   |
| Common Stock                    | 10/05/2016                           |  | J <sup>(1)</sup>               | 195,400 D   | \$ 0 195,392  | I  | By Trust  |
| Common Stock                    |                                      |  |                                |   | 80,000  | I  | Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO |

|              |        |   |   |
|--------------|--------|---|---|
| Common Stock | 80,000 | I | Bridget Elise Went<br>Gregory T Went & Marjorie S Went ttees<br>2012 Irr Trust FBO Cora Margaret Went |
|--------------|--------|---|---|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount or Number of Shares                              |
| Stock Option (Right to Buy)                | \$ 0.665   | 10/05/2016                           |  | J <sup>(1)</sup>               | 121,784   | <sup>(2)</sup> 11/16/2021                                | Common Stock 121,784  |
| Stock Option (Right to Buy)                | \$ 0.665   | 10/05/2016                           |  | J <sup>(1)</sup>               | 27,995  | <sup>(3)</sup> 02/22/2022                                | Common Stock 27,995   |
| Stock Option (Right to Buy)                | \$ 8.995   | 10/05/2016                           |  | J <sup>(1)</sup>               | 262,963   | <sup>(4)</sup> 02/20/2024                                | Common Stock 262,963  |
| Stock Option (Right to Buy)                | \$ 17.31   | 10/05/2016                           |  | J <sup>(1)</sup>               | 9,439   | <sup>(5)</sup> 02/24/2025                                | Common Stock 9,439  |

